This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233.10.1038/361226a08380905VetrieDVorechovskyISiderasPHollandJDaviesAFlinterFThe gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinasesNature1993361226233Open DOISearch in Google Scholar
Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279–290.10.1016/0092-8674(93)90667-FTsukadaSSaffranDCRawlingsDJParoliniOAllenRCKlisakIDeficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell199372279290Open DOISearch in Google Scholar
Thomas DJ, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 1993;261:355–8.833290010.1126/science.8332900ThomasDJSiderasPSmithCIVorechovskyIChapmanVPaulWE.Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genesScience19932613558Search in Google Scholar
Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61.833290110.1126/science.8332901RawlingsDJSaffranDCTsukadaSLargaespadaDAGrimaldiJCCohenLMutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID miceScience199326135861Search in Google Scholar
Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res. 2001;23(2-3):147-56.1144438010.1385/IR:23:2-3:147KhanWN.Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinaseImmunol Res.2001232-314756Search in Google Scholar
Fruman DA, Satterthwaite AB, Witte ON. Xid-like phenotypes: a B cell signalosome takes shape. Immunity. 2000;13(1):1-3.10.1016/S1074-7613(00)00002-9FrumanDASatterthwaiteABWitteON.Xid-like phenotypes: a B cell signalosome takes shapeImmunity200013113Open DOISearch in Google Scholar
Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152:557–565.SmithCIBaskinBHumire-GreiffPZhouJNOlssonPGManiarHSExpression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cellsJ Immunol199415255756510.4049/jimmunol.152.2.557Search in Google Scholar
Mohamed AJ, Yu L, Bäckesjö CM, Vargas L, Faryal R, Aints A et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.10.1111/j.1600-065X.2008.00741.xMohamedAJYuLBäckesjöCMVargasLFaryalRAintsABruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainImmunol Rev200922815873Open DOISearch in Google Scholar
Mohamed AJ, Nore BF, Christensson B, Smith CI. Signalling of Bruton’s tyrosine kinase, Btk. Scand J Immunol. 1999;49(2):113-8.10.1046/j.1365-3083.1999.00504.x10075013MohamedAJNoreBFChristenssonBSmithCI.Signalling of Bruton’s tyrosine kinase, BtkScand J Immunol1999492113810075013Open DOISearch in Google Scholar
Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2(12):945-56.10.1038/nri95512461567NiiroHClarkEA.Regulation of B-cell fate by antigen-receptor signalsNat Rev Immunol20022129455612461567Open DOISearch in Google Scholar
Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296(5573):1641-2.1204017710.1126/science.1071546GauldSBDal PortoJMCambierJC.B cell antigen receptor signaling: roles in cell development and diseaseScience200229655731641212040177Search in Google Scholar
Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T et al. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med. 1994;179(5):1725-9.10.1084/jem.179.5.1725KurosakiTTakataMYamanashiYInazuTTaniguchiTYamamotoTSyk activation by the Src-family tyrosine kinase in the B cell receptor signalingJ Exp Med1994179517259Open DOISearch in Google Scholar
Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med. 1995;182(6):1815-23.10.1084/jem.182.6.1815KurosakiTJohnsonSAPaoLSadaKYamamuraHCambierJC.Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signalingJ Exp Med19951826181523Open DOISearch in Google Scholar
Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependentmembrane association of the Bruton’s tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem 1999;274(16):10983–10989.10.1074/jbc.274.16.1098310196179VarnaiPRotherKIBallaT.Phosphatidylinositol 3-kinase-dependentmembrane association of the Bruton’s tyrosine kinase pleckstrin homology domain visualized in single living cellsJ Biol Chem1999274161098310989Open DOISearch in Google Scholar
Yang W, Desiderio S. BAP-135, a target for Bruton’s tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci U S A. 1997;94(2):604–609.10.1073/pnas.94.2.604YangWDesiderioS.BAP-135, a target for Bruton’s tyrosine kinase in response to B cell receptor engagementProc Natl Acad Sci U S A.1997942604609Open DOISearch in Google Scholar
Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996;4(5):515–525.10.1016/S1074-7613(00)80417-38630736ParkHWahlMIAfarDETurckCWRawlingsDJTamCRegulation of Btk function by a major autophosphorylation site within the SH3 domainImmunity.199645515525Open DOISearch in Google Scholar
Rodriguez R, Matsuda M, Perisic O, Bravo J, Paul A, Jones NP et al. Tyrosine residues in phospholipase Cgamma2 essential for the enzyme function in B-cell signaling. J BiolChem. 2001;276(51):47982– 47992.RodriguezRMatsudaMPerisicOBravoJPaulAJonesNPTyrosine residues in phospholipase Cgamma2 essential for the enzyme function in B-cell signalingJ BiolChem.2001276514798247992Search in Google Scholar
Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N et al. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem. 2004;279(36):37651-61.10.1074/jbc.M31198520015184383HumphriesLADangelmaierCSommerKKippKKatoRMGriffithNTec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linkerJ Biol Chem2004279363765161Open DOISearch in Google Scholar
Liu JL, Chiles TC, Sen RJ, Rothstein TL. Inducible nuclear expression of NF-kappa B in primary B cells stimulated through the surface Ig receptor. J Immunol. 1991;146(5):1685-91.1993849LiuJLChilesTCSenRJRothsteinTL.Inducible nuclear expression of NF-kappa B in primary B cells stimulated through the surface Ig receptorJ Immunol1991146516859110.4049/jimmunol.146.5.1685Search in Google Scholar
Saito K, Tolias KF, Saci A, Koon HB, Humphries LA, Scharenberg A et al. BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity. 2003;19(5):669-78.1461485410.1016/S1074-7613(03)00297-8SaitoKToliasKFSaciAKoonHBHumphriesLAScharenbergABTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activityImmunity200319566978Search in Google Scholar
de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93-104.10.1016/j.immuni.2006.11.01217239630de GorterDJBeulingEAKersseboomRMiddendorpSvan GilsJMHendriksRWBruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homingImmunity.2007269310417239630Open DOISearch in Google Scholar
Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol. 2006;36:1285-1295.10.1002/eji.200535799OrtolanoSHwangIYHanSBKehrlJH.Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homingEur J Immunol.2006361285129516619289Open DOISearch in Google Scholar
Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264(6):549-62.1901717910.1111/j.1365-2796.2008.02030.xGhiaPChiorazziNStamatopoulosK.Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulationJ Intern Med200826465496219017179Search in Google Scholar
Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103.22160019BurgerJA.Nurture versus nature: the microenvironment in chronic lymphocytic leukemiaHematology Am Soc Hematol Educ Program.201120119610310.1182/asheducation-2011.1.9622160019Search in Google Scholar
Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515– 25.10.1172/JCI30099788964FaisFGhiottoFHashimotoSSellarsBValettoAAllenSLChronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptorsJ Clin Invest19981021515255090019788964Open DOISearch in Google Scholar
Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-94.10.1146/annurev.immunol.21.120601.141018ChiorazziNFerrariniM.B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptorAnnu Rev Immunol.2003218419412615894Open DOISearch in Google Scholar
Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111(3):1524-1533.17959859MurrayFDarzentasNHadzidimitriouATobinGBoudjograMScielzoCStereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesisBlood200811131524153310.1182/blood-2007-07-09956417959859Search in Google Scholar
Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, Karlsson K et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101:4952–7.10.1182/blood-2002-11-348512586612TobinGThunbergUJohnsonAErikssonISoderbergOKarlssonKChronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitopeBlood20031014952712586612Open DOISearch in Google Scholar
Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104:2499–504.1521782810.1182/blood-2004-03-0818WidhopfGF 2ndRassentiLZToyTLGribbenJGWierdaWGKippsTJ.Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulinsBlood2004104249950415217828Search in Google Scholar
Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519–25.1531407710.1084/jem.20040544MessmerBTAlbesianoEEfremovDGGhiottoFAllenSLKolitzJMultiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemiaJ Exp Med200420051925221193615314077Search in Google Scholar
Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879–85.10.1182/blood-2004-01-013215217826TobinGThunbergUKarlssonKMurrayFLaurellAWillanderKSubsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemiaBlood200410428798515217826Open DOISearch in Google Scholar
Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood. 2003;101:3082–4.10.1182/blood-2002-08-243212480699PotterKNOrchardJCritchleyEMockridgeCIJoseAStevensonFK.Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoireBlood20031013082412480699Open DOISearch in Google Scholar
Widhopf GF 2nd, Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001;166: 95–102.10.4049/jimmunol.166.1.9511123281WidhopfGF 2ndKippsTJ.Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cellsJ Immunol.20011669510211123281Open DOISearch in Google Scholar
Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-95.1496289710.1182/blood-2003-12-4312StevensonFKCaligaris-CappioF.Chronic lymphocytic leukemia: revelations from the B-cell receptorBlood20041031243899514962897Search in Google Scholar
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.10.1056/NEJMra04172015728813ChiorazziNRaiKRFerrariniM.Chronic lymphocytic leukemiaN Engl J Med200535288041515728813Open DOISearch in Google Scholar
Darzentas N, Hadzidimitriou A, Murray F, Hatzi K, Josefsson P, Laoutaris N et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia. 2010;24(1):125-132.10.1038/leu.2009.18619759557DarzentasNHadzidimitriouAMurrayFHatziKJosefssonPLaoutarisNA different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidenceLeukemia201024112513219759557Open DOISearch in Google Scholar
Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109(10):4424-31.1725535510.1182/blood-2006-11-056648MockridgeCIPotterKNWheatleyINevilleLAPackhamGStevensonFK.Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational statusBlood20071091044243117255355Search in Google Scholar
Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313-20.2181683310.1182/blood-2011-06-338855StevensonFKKrysovSDaviesAJSteeleAJPackhamG.B-cell receptor signaling in chronic lymphocytic leukemiaBlood20111181643132021816833Search in Google Scholar
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein Harald et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2008;2:180-2.SwerdlowSHCampoEHarrisNLJaffeESPileriSASteinHaraldWHO Classification of Tumours of Haematopoietic and Lymphoid TissuesIARC PressLyon200821802Search in Google Scholar
Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118(11):3088-95.10.1182/blood-2011-03-343434HadzidimitriouAAgathangelidisADarzentasNMurrayFDelfau-LarueMHPedersenLBIs there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 casesBlood20111181130889521791422Open DOISearch in Google Scholar
Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38.2094041510.1182/blood-2010-04-189977Pérez-GalánPDreylingMWiestnerA.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBlood201111712638303774720940415Search in Google Scholar
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.10.1038/nature0863820054396DavisRENgoVNLenzGTolarPYoungRMRomesserPBChronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature201046372778892284553520054396Open DOISearch in Google Scholar
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.10.1200/JCO.2012.42.790623045577AdvaniRHBuggyJJSharmanJPSmithSMBoydTEGrantBBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol20133118894550516623045577Open DOISearch in Google Scholar
Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013;122(7):1222-32.10.1182/blood-2012-12-47511123836557YangGZhouYLiuXXuLCaoYManningRJA mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood2013122712223223836557Open DOISearch in Google Scholar
Fernandez-Vega I, Quiros LM, Santos-Juanes J, Pane-Foix M, Marafioti T. Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Arch. 2015;466:229-235.10.1007/s00428-014-1698-zFernandez-VegaIQuirosLMSantos-JuanesJPane-FoixMMarafiotiT.Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphomaVirchows Arch.2015466229235Open DOISearch in Google Scholar
Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in Refractory Classic Hodgkin’s Lymphoma. N Engl J Med. 2015;373(14):1381-2.2642274310.1056/NEJMc1505857HamadaniMBalasubramanianSHariPN.Ibrutinib in Refractory Classic Hodgkin’s LymphomaN Engl J Med20153731413812Search in Google Scholar
Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.10.1186/1756-8722-6-8824261963AkinleyeAAvvaruPFurqanMSongYLiuD.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsJ Hematol Oncol.20136188Open DOISearch in Google Scholar
ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res. 2014;20(3):548-56.10.1158/1078-0432.CCR-13-022624323900ten HackenEBurgerJA.Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptorClin Cancer Res201420354856Open DOISearch in Google Scholar
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080.2061596510.1073/pnas.1004594107HonigbergLASmithAMSirisawadMVernerELouryDChangBThe Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProc Natl Acad Sci U S A.2010107291307513080Search in Google Scholar
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-96.10.1182/blood-2011-01-32848421422473HermanSEGordonALHertleinERamanunniAZhangXJaglowskiSBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood201111723628796Open DOISearch in Google Scholar
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-9.10.1182/blood-2011-10-38641722180443PonaderSChenSSBuggyJJBalakrishnanKGandhiVWierdaWGThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood2012119511829Open DOISearch in Google Scholar
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.10.1056/NEJMoa121563723782158ByrdJCFurmanRRCoutreSEFlinnIWBurgerJABlumKATargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaN Engl J Med201336913242Open DOISearch in Google Scholar
O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.10.1016/S1470-2045(13)70513-824332241O’BrienSFurmanRRCoutreSESharmanJPBurgerJABlumKAIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialLancet Oncol20141514858Open DOISearch in Google Scholar
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-23.2488163110.1056/NEJMoa1400376ByrdJCBrownJRO’BrienSBarrientosJCKayNEReddyNMRESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med2014371321323413452124881631Search in Google Scholar
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-506.2570043210.1182/blood-2014-10-606038ByrdJCFurmanRRCoutreSEBurgerJABlumKAColemanMThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood2015125162497506440028825700432Search in Google Scholar
Burger JA, Tedeschi A, Barr PM, Tadeusz R, Owen C, Ghia P et al. RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-37.2663914910.1056/NEJMoa1509388BurgerJATedeschiABarrPMTadeuszROwenCGhiaPRESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaN Engl J Med201537325242537472280926639149Search in Google Scholar
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16.10.1056/NEJMoa130622023782157WangMLRuleSMartinPGoyAAuerRKahlBSTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaN Engl J Med2013369650716451394123782157Open DOISearch in Google Scholar
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B et al. (2014b) Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study. Blood. (ASH Annual Meeting Abstracts) abstract 4453.WangMRuleSMartinPGoyAAuerRKahlB2014bSingle-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 studyBlood.(ASH Annual Meeting Abstracts)abstract 445310.1182/blood.V124.21.4453.4453Search in Google Scholar
Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015;6(5):242-52.2642533710.1177/2040620715592569StephensDMSpurgeonSE.Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionTher Adv Hematol20156524252455696926425337Search in Google Scholar
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430-40.10.1056/NEJMoa150154825853747TreonSPTripsasCKMeidKWarrenDVarmaGGreenRIbrutinib in previously treated Waldenström’s macroglobulinemiaN Engl J Med20153721514304025853747Open DOISearch in Google Scholar
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-6.10.1038/nm.388426193343WilsonWHYoungRMSchmitzRYangYPittalugaSWrightGTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNat Med20152189226837224526193343Open DOISearch in Google Scholar
Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.10.1186/s13045-016-0250-926957112WuJZhangMLiuD.Acalabrutinib (ACP-196): a selective second-generation BTK inhibitorJ Hematol Oncol.2016921478445926957112Open DOISearch in Google Scholar
